Protalix BioTherapeutics Inc (DE)

Financials

총자산 67.93 M73.67 M55.79 M84.43 M73.42 M82.35 M 총 부채 94.97 M79.7 M66.43 M50.87 M30.21 M34.12 M 자본금 총액 -27.04 M-6.04 M-10.64 M33.57 M43.21 M48.23 M 총 부채 및 주주자본 67.93 M73.67 M55.79 M84.43 M73.42 M82.35 M 총부채 —27.89 M28.19 M——— 순부채 —-11.1 M11.08 M———

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

PLX

Financials

Protalix BioTherapeutics Inc (DE)

뉴스

Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX)

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX)

Brazil judge overrules decisions suspending changes to meal voucher system

A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)

Pluxee, 이디 주가, 긍정적 실적 및 전망 발표 후 급등

Pluxee, Edenred shares jump after upbeat results and outlook

Pluxee 2026년 1분기: 브라질 난관 속 9% 매출 성장

Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds

프로탈릭스, 통제불능 통풍 치료에 집중하는 2026년 전략 발표

Tuesday’s Insider Activity: Key Execs Make Notable Trades

바샨 드로어, 프로탈릭스 바이오테라퓨틱스 CEO, 10만 1천 달러 상당 주식 매수

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)